➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Mallinckrodt
Boehringer Ingelheim
Medtronic
Moodys

Last Updated: October 23, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR INTERFERON BETA-1B

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for interferon beta-1b

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000401 ↗ Oral Collagen for Rheumatoid Arthritis Completed National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Phase 2 1999-07-01 Rheumatoid arthritis (RA) is an autoimmune disease characterized by swelling and inflammation of the joints. In RA, the immune system attacks a person's own cells inside joints, eventually leading to joint damage and disability. This study will determine if oral bovine type II collagen (bovine CII) will lead to decreased joint inflammation in RA patients.
NCT00000401 ↗ Oral Collagen for Rheumatoid Arthritis Completed University of Tennessee Phase 2 1999-07-01 Rheumatoid arthritis (RA) is an autoimmune disease characterized by swelling and inflammation of the joints. In RA, the immune system attacks a person's own cells inside joints, eventually leading to joint damage and disability. This study will determine if oral bovine type II collagen (bovine CII) will lead to decreased joint inflammation in RA patients.
NCT00000647 ↗ An Open Trial Combining Zidovudine, Interferon-alfa, and Recombinant CD4-IgG With Transplantation of Syngeneic Bone Marrow and Peripheral Blood Lymphocytes From Healthy gp160-Immunized Donors in the Treatment of Patients With HIV Infection Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A 1969-12-31 To restore immunologic function and virus-free state in HIV-infected patients. Based on previous studies showing temporary improvement in immune function in HIV-infected patients using peripheral lymphocyte transfers and bone marrow transplantation, and based on studies documenting the antiretroviral effects of zidovudine (AZT) and interferon-alfa (IFN-A) as well as the preliminary test tube and patient studies suggesting anti-HIV effects of recombinant CD4-IgG, we propose to treat HIV-infected patients using combination antiretroviral therapy with transplantation of bone marrow and peripheral lymphocytes from previously immunized donors in an attempt to restore immunologic function and a virus-free state.
NCT00000687 ↗ Phase II Study of Zidovudine and Recombinant Alpha-2A Interferon in the Treatment of Patients With AIDS-Associated Kaposi's Sarcoma Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 1969-12-31 To determine the safety and effectiveness of combining zidovudine (AZT) and interferon alfa-2a (IFN-A2a) in a treatment for Kaposi's sarcoma (KS) in patients who have AIDS. It is hoped with the present study to define the rate at which the treatment affects the tumors and also to assess any toxic effects of the combination treatment over a period of time. In a recent study, the combination of IFN-A2a and AZT in the treatment of patients with AIDS-associated KS was evaluated and safe doses of both AZT and IFN-A2a were determined. In addition, it appeared that there was a substantial reduction in KS lesions with this therapy. Potential benefits of this combined therapy include resolution of KS lesions, prolonged survival, a decrease in the frequency and severity of opportunistic infections, improvement in CD4 cells, and a decrease in serum p24 antigens.
NCT00000694 ↗ A Phase I Trial of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (rHuGM-CSF), Recombinant Alpha Interferon and Azidothymidine (AZT) in AIDS-Associated Kaposi's Sarcoma Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 1 1969-12-31 To define the best doses of sargramostim ( granulocyte-macrophage colony-stimulating factor; GM-CSF ), interferon alfa-2b ( IFN-A2b ), and zidovudine ( AZT ) to give together in patients with AIDS-associated Kaposi's sarcoma ( KS ), to learn about the side effects of these drugs when they are given together for 8 weeks, and to find out whether the combination of GM-CSF, IFN-A2b, and AZT has any effect on KS, HIV, or the immune system. Studies show that IFN-A2b can cause KS tumors to shrink or disappear in about 30 percent of patients. IFN-A2b can greatly reduce the growth of the HIV virus in test tube experiments and perhaps in patients. AZT has also been shown to reduce the growth of HIV and show improvements in the immune system with fewer infections. Test tube experiments show that when IFN-A2b and AZT are used together, they reduce the growth of the HIV virus much more effectively than when either drug is used alone. In recent studies of the combination of interferon alpha and AZT in patients with KS, more than 40 percent of the patients showed shrinkage of their tumors, and some showed evidence for suppression of HIV growth in the body. However, the combination of IFN-A2b with AZT often caused a marked lowering of the white blood cell (WBC) count, especially a type of WBC called the granulocyte (or neutrophil) which is important in the body's defense against infection. Recombinant human GM-CSF is a human protein which is produced in bacteria. It has been shown to cause an increase in the WBC count.
NCT00000695 ↗ Open Label Phase I Study To Evaluate the Safety of Combination Therapy With AZT and Interferon-Beta in Patients With AIDS Related Kaposi's Sarcoma Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 1 1969-12-31 To determine the highest tolerated dose of the safety and tolerance of interferon beta (IFN-B) when it is given at the same time as zidovudine (AZT) to patients with early AIDS related Kaposi's sarcoma. In addition, the studies will determine preliminary data on response, immune function, and subcutaneous absorption. IFN-B has demonstrated a dose-dependent ability to suppress the replication of HIV in the test tube. In addition, previous studies have shown AZT to be an effective inhibitor of HIV reverse transcriptase; Phase I and II study benefits of AZT treatment include increased objective clinical improvement, decreased mortality rate, and decreased incidence of opportunistic infections. Long-term AZT use, however, presents possible limitations secondary to intolerance. This study, therefore, will investigate the potential antiviral activities of a combination of IFN-B and AZT to determine the safety and efficacy of such treatment in patients with AIDS related Kaposi's sarcoma. It is believed that combination drug therapy consisting of low doses of each drug will reduce the potential of toxicity, treatment failures, and disease recurrences resulting from drug-resistant virus mutants.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for interferon beta-1b

Condition Name

Condition Name for interferon beta-1b
Intervention Trials
Hepatitis C 216
Hepatitis C, Chronic 137
Chronic Hepatitis C 124
Multiple Sclerosis 81
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for interferon beta-1b
Intervention Trials
Hepatitis 662
Hepatitis C 592
Hepatitis A 539
Hepatitis, Chronic 356
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for interferon beta-1b

Trials by Country

Trials by Country for interferon beta-1b
Location Trials
Canada 358
Germany 304
Brazil 96
Poland 93
Belgium 86
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for interferon beta-1b
Location Trials
Texas 252
California 240
New York 229
Maryland 204
Florida 165
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for interferon beta-1b

Clinical Trial Phase

Clinical Trial Phase for interferon beta-1b
Clinical Trial Phase Trials
Phase 4 266
Phase 3 369
Phase 2/Phase 3 57
[disabled in preview] 915
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for interferon beta-1b
Clinical Trial Phase Trials
Completed 907
Recruiting 249
Not yet recruiting 196
[disabled in preview] 373
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for interferon beta-1b

Sponsor Name

Sponsor Name for interferon beta-1b
Sponsor Trials
National Cancer Institute (NCI) 146
Hoffmann-La Roche 95
Merck Sharp & Dohme Corp. 83
[disabled in preview] 169
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for interferon beta-1b
Sponsor Trials
Other 1606
Industry 954
NIH 296
[disabled in preview] 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Baxter
Merck
Medtronic
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.